Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Opinions on the Review of the NHI Pricing Rule (Excerpt) Presented by the FPMAJ
June 15, 2009
- More Drugs Granted Premiums: Mr Nakagaki
June 15, 2009
- Sandoz's Somatropin to Be Approved as 1st Biosimilar Based on New Guidance
June 15, 2009
- R&D NEWS IN BRIEF
June 8, 2009
- Chuikyo Subcommittee to Review Whether Price Gaps Promote Use of Generics
June 8, 2009
- Sleep Disorders Increase Risk of Other Diseases
June 8, 2009
- Sawai: Sales, Profits Up Driven by Gov't Policy to Promote Use of Generics
June 8, 2009
- Only 20% of Mothers Talk to Daughters about GYN Diseases
June 8, 2009
- Publicity on RLS Essential for Patients, Physicians
June 8, 2009
- REGULATORY NEWS IN BRIEF
June 8, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 8, 2009
- Atul Sobti Named CEO of Ranbaxy
June 8, 2009
- NBI's Sales Exceeded Industry Average for Five Consecutive Years: Dr T. Heil
June 8, 2009
- Towa: New Products Listed in 2008 Drive Sales
June 8, 2009
- Takeda Licenses Hib Vaccine from Novartis
June 8, 2009
- Nichi-Iko to Create Joint Venture with Mitani Sangyo to Manufacture Raw Materials for Generics
June 8, 2009
- Daiichi Sankyo Revises Net Loss from ¥335.8 Bil. to ¥215.5 Bil.
June 8, 2009
- Korosho to Call For Stricter Adherence to Ryotan-kisoku for Use of More Generics
June 8, 2009
- Co-DIO, Ecard Ranked No. 1 and 2 on Both GP and HP Markets
June 8, 2009
- Rohto: Sales Up 16th Year in a Row
June 8, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…